This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
BioTime (BTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
BioTime (BTX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd
Earnings Preview: BioTime (BTX) Q3 Earnings Expected to Decline
by Zacks Equity Research
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yields on US Treasury Notes Hit Record High: 5 Bank Picks
by Nalak Das
A hike in interest rate will raise the cost of funds, which in turn will enable the financial sector, especially banks
Can The Uptrend Continue for BioTime (BTX)?
by Zacks Equity Research
Investors certainly have to be happy with BioTime, Inc. (BTX) and its short term performance.
BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioTime (BTX) delivered earnings and revenue surprises of 33.33% and 671.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?